Premier sponsor

M42

 

 

M24

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. 

Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.

Learn more (opens in a new tab)

 

Strategic sponsor

Ajinomoto

 

 

Ajinomoto/Forge Biologics

 

For more than a century, the Ajinomoto Group has pioneered the science of amino acids, building expertise that has expanded into healthcare and life sciences.

Today, through “AminoScience,” our unique scientific approach rooted in amino acid research, we apply this knowledge and evolving technologies to contribute to the well-being of people, society, and the planet.

This scientific foundation extends to the development and manufacture of next-generation therapeutics through Ajinomoto Bio-Pharma Services. Ajinomoto Bio-Pharma Services, including Forge Biologics, is a global network of specialized CDMOs and enabling technologies spanning small molecules, oligonucleotides, peptides, proteins, antibody-drug conjugates (ADCs), and gene therapies. With proprietary platforms including AJIPHASE™, CORYNEX™, and AJICAP™, we help pharmaceutical and biotechnology partners advance next-generation medicines from development through commercialization and ultimately to patients worldwide.

For more information, visit ajibio-pharma.ajinomoto.com.